It has been an incredibly insightful experience for Asphalion’s experts Lidia Cánovas, Helen Chen and Imma Ferrera to engage with key stakeholders involved in shaping the new general pharmaceutical legislation, learn from industry perspectives, and delve into discussions shaping the future of healthcare regulation in Europe at the DIA RAPS Regulatory Policy Forum in Brussels this week.
Our experts have been able to participate in the main conclusions from roundtable sessions and in dynamic panels with leading stakeholders.
Furthermore, they have been able to dive deep into the New General Pharmaceutical Legislation (GPL), participating in interactive roundtables focused on:
- The Paediatrics elements within the GPL
- Orphan medicines and defining (high) unmet medical needs
- Europe’s evolving role in global expedited pathways—OPEN, PRIME, and MAA assessment timelines
- The interface between Scientific Advice and Health Technology Assessment (HTA)
We are excited to continue contributing to these important conversations and supporting the evolution of pharmaceutical regulation. Thank you to everyone involved in this fantastic event!
Need help for your regulatory endeavours? Contact us! [email protected]
